ANI Pharmaceuticals will report Q2 2026 results before market open, with consensus estimates at $2.04 EPS and $260.13M revenue.
ANI Pharmaceuticals (ANIP) will announce its Q2 2026 earnings on August 7 before the market opens. Analysts expect earnings per share of $2.04, reflecting a 13.3% year-over-year increase, and revenue of $260.13M, up 23.1% from the same period last year.
The company has shown consistent growth over the past two years, though specific prior quarter comparisons were not detailed. Consensus estimates suggest strong performance, aligning with broader sector trends in pharmaceuticals.
No immediate market reaction details were provided ahead of the release.